$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

$eltp Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223041124 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3
Revenue	$15.54M	$14.16M
YoY Change	67.99%	64.89%
Cost Of Revenue	$8.498M	$7.710M
YoY Change	96.21%	61.93%
Gross Profit	$7.041M	$6.447M
YoY Change	43.13%	68.58%
Gross Profit Margin	45.31%	45.54%
Selling, General & Admin	$1.761M	$1.576M
YoY Change	46.87%	31.72%
% of Gross Profit	25.01%	24.45%
Research & Development	$1.404M	$2.618M
YoY Change	-2.74%	113.35%
% of Gross Profit	19.94%	40.61%
Depreciation & Amortization	$336.6K	$327.2K
YoY Change	6.99%	3.55%
% of Gross Profit	4.78%	5.08%
Operating Expenses	$3.508M	$4.522M
YoY Change	18.52%	64.82%
Operating Profit	$3.533M	$1.926M
YoY Change	80.32%	78.1%
Interest Expense	$121.6K	$130.4K
YoY Change	-62.31%	-46.27%
% of Operating Profit	3.44%	6.77%
Other Income/Expense, Net	-$3.627M	-$4.658M
YoY Change	-445.35%	-1145.38%
Pretax Income	-$94.26K	-$2.733M
YoY Change	-103.13%	-279.0%
Income Tax	-$800.0K	-$17.70M
% Of Pretax Income
Net Earnings	$706.4K	$14.93M
YoY Change	-76.22%	885.69%
Net Earnings / Revenue	4.55%	105.49%
Basic Earnings Per Share	$0.00	$0.01
Diluted Earnings Per Share	$0.00	$0.01
COMMON SHARES
Basic Shares Outstanding	1.014B shares	1.014B shares
Diluted Shares Outstanding	1.024B shares	1.019B shares

Balance Sheet

Concept	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.816M	$8.654M
YoY Change	-67.52%	-53.36%
Cash & Equivalents	$5.816M	$8.654M
Short-Term Investments
Other Short-Term Assets	$1.006M	$355.6K
YoY Change	-9.24%	61.73%
Inventory	$14.33M	$15.22M
Prepaid Expenses
Receivables	$16.01M	$10.50M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$37.16M	$34.73M
YoY Change	12.04%	13.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.10M	$9.770M
YoY Change	-1.32%	-7.34%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$7.260K	$21.02K
YoY Change	-92.09%	-77.09%
Other Assets	$20.66M	$19.86M
YoY Change	701.77%	670.51%
Total Long-Term Assets	$37.54M	$35.99M
YoY Change	92.01%	81.12%
TOTAL ASSETS
Total Short-Term Assets	$37.16M	$34.73M
Total Long-Term Assets	$37.54M	$35.99M
Total Assets	$74.70M	$70.72M
YoY Change	41.7%	40.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.891M	$3.609M
YoY Change	96.35%	109.39%
Accrued Expenses	$11.88M	$11.16M
YoY Change	154.15%	143.71%
Deferred Revenue	$13.33K	$13.33K
YoY Change	0.0%	0.0%
Short-Term Debt	$4.000M	$4.000M
YoY Change
Long-Term Debt Due	$343.9K	$295.2K
YoY Change	-27.06%	-41.28%
Total Short-Term Liabilities	$19.16M	$19.08M
YoY Change	187.91%	178.79%
LONG-TERM LIABILITIES
Long-Term Debt	$3.518M	$3.355M
YoY Change	-77.29%	-78.4%
Other Long-Term Liabilities	$5.606M	$3.192M
YoY Change
Total Long-Term Liabilities	$9.124M	$6.547M
YoY Change	-42.57%	-59.86%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.16M	$19.08M
Total Long-Term Liabilities	$9.124M	$6.547M
Total Liabilities	$28.28M	$25.62M
YoY Change	25.47%	10.68%
SHAREHOLDERS EQUITY
Retained Earnings	-$119.7M	-$120.4M
YoY Change	-11.5%	-12.89%
Common Stock	$1.018M	$1.014M
YoY Change	0.38%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$306.8K	$306.8K
YoY Change	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	$46.41M	$45.09M
YoY Change
Total Liabilities & Shareholders Equity	$74.70M	$70.72M
YoY Change	41.7%	40.47%

Cashflow Statement

Concept	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	$706.4K	$14.93M
YoY Change	-76.22%	885.69%
Depreciation, Depletion And Amortization	$336.6K	$327.2K
YoY Change	6.99%	3.55%
Cash From Operating Activities	-$2.396M	-$235.9K
YoY Change	321.88%	-115.78%
INVESTING ACTIVITIES
Capital Expenditures	$406.0K	$0.00
YoY Change	57084.51%	-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$406.0K	$0.00
YoY Change	57084.51%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-30.66K	-179.5K
YoY Change	-60.37%	-107.53%
NET CHANGE
Cash From Operating Activities	-2.396M	-235.9K
Cash From Investing Activities	-406.0K	0.000
Cash From Financing Activities	-30.66K	-179.5K
Net Change In Cash	-2.832M	-415.4K
YoY Change	338.49%	-66.08%
FREE CASH FLOW
Cash From Operating Activities	-$2.396M	-$235.9K
Capital Expenditures	$406.0K	$0.00
Free Cash Flow	-$2.802M	-$235.9K
YoY Change	392.76%	-103.57%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Entity Central Index Key EntityCentralIndexKey	0001053369
CY2022Q3	ELTP	Change In Fair Value Of Stockbased Liabilities ChangeInFairValueOfStockbasedLiabilities		usd
	ELTP	Change In Fair Value Of Stockbased Liabilities ChangeInFairValueOfStockbasedLiabilities		usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
	ELTP	Change In Fair Value Of Stockbased Liabilities ChangeInFairValueOfStockbasedLiabilities		usd
	ELTP	Deferred Income Tax Asset DeferredIncomeTaxAsset		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	ELTP	Finitelived Intangible Assets Impairment FinitelivedIntangibleAssetsImpairment		usd
CY2023Q3	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther		usd
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther		usd
CY2022Q3	us-gaap	Dilutive Securities DilutiveSecurities		usd
	us-gaap	Dilutive Securities DilutiveSecurities		usd
CY2023Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent		usd
CY2023Q1	ELTP	Codevelopment Profit Split Accrued CodevelopmentProfitSplitAccrued		usd
CY2023Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent		usd
CY2023Q1	us-gaap	Litigation Reserve Current LitigationReserveCurrent		usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent		usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount		usd
	ELTP	Awarded Shares AwardedShares		usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-15697
	dei	Entity Registrant Name EntityRegistrantName	ELITE PHARMACEUTICALS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	22-3542636
	dei	Entity Address Address Line1 EntityAddressAddressLine1	165 LUDLOW AVENUE
	dei	Entity Address City Or Town EntityAddressCityOrTown	NORTHVALE
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07647
	dei	City Area Code CityAreaCode	201
	dei	Local Phone Number LocalPhoneNumber	750-2646
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	ELTP
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1013915081	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8653903	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7832247	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	125000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10495061	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3094549	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	15224384	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	9550716	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	355561	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1032785	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	34728909	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	21510297	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15241857	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14586335	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9769981	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10426158	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6341228	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6341228	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1899	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13062	usd
CY2023Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	19433168	usd
CY2023Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	2171821	usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	422750	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	412434	usd
CY2023Q3	us-gaap	Security Deposit SecurityDeposit	21018	usd
CY2023Q1	us-gaap	Security Deposit SecurityDeposit	21018	usd
CY2023Q3	us-gaap	Other Assets OtherAssets	443768	usd
CY2023Q1	us-gaap	Other Assets OtherAssets	433452	usd
CY2023Q3	us-gaap	Assets Assets	70718953	usd
CY2023Q1	us-gaap	Assets Assets	40896018	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3608993	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2446810	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11158268	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5047726	usd
CY2023Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	13333	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	13333	usd
CY2023Q3	us-gaap	Secured Debt Current SecuredDebtCurrent	115822	usd
CY2023Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	110822	usd
CY2023Q3	us-gaap	Loans Payable Current LoansPayableCurrent	179325	usd
CY2023Q1	us-gaap	Loans Payable Current LoansPayableCurrent	200032	usd
CY2023Q3	us-gaap	Other Loans Payable OtherLoansPayable	4000000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2163	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	14914	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	19077904	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	7833637	usd
CY2023Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	12222	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	18890	usd
CY2023Q3	us-gaap	Secured Long Term Debt SecuredLongTermDebt	902568	usd
CY2023Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	1029018	usd
CY2023Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable	2452384	usd
CY2023Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	2532502	usd
CY2023Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	3179428	usd
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	521711	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	6546602	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4102121	usd
CY2023Q3	us-gaap	Liabilities Liabilities	25624506	usd
CY2023Q1	us-gaap	Liabilities Liabilities	11935758	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1445000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1445000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1014015081	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1014015081	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1013915081	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1013915081	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	1014019	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	1014019	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	164808757	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	164750980	usd
CY2023Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	100000	shares
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	100000	shares
CY2023Q3	us-gaap	Treasury Stock Value TreasuryStockValue	306841	usd
CY2023Q1	us-gaap	Treasury Stock Value TreasuryStockValue	306841	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-120421488	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-136497898	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	45094447	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	28960260	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	70718953	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40896018	usd
CY2023Q3	ELTP	Revenue From Manufacturing Fees RevenueFromManufacturingFees	13507870	usd
CY2022Q3	ELTP	Revenue From Manufacturing Fees RevenueFromManufacturingFees	7187363	usd
	ELTP	Revenue From Manufacturing Fees RevenueFromManufacturingFees	21417107	usd
	ELTP	Revenue From Manufacturing Fees RevenueFromManufacturingFees	13514504	usd
CY2023Q3	ELTP	Revenue From Licensing Fees RevenueFromLicensingFees	649315	usd
CY2022Q3	ELTP	Revenue From Licensing Fees RevenueFromLicensingFees	1398400	usd
	ELTP	Revenue From Licensing Fees RevenueFromLicensingFees	1720154	usd
	ELTP	Revenue From Licensing Fees RevenueFromLicensingFees	2744167	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14157185	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8585763	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	23137261	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16258671	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	7710106	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	4761329	usd
	us-gaap	Cost Of Revenue CostOfRevenue	11939627	usd
	us-gaap	Cost Of Revenue CostOfRevenue	8436390	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	6447079	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	3824434	usd
	us-gaap	Gross Profit GrossProfit	11197634	usd
	us-gaap	Gross Profit GrossProfit	7822281	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2618349	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1227269	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3761894	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2182712	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1533208	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1190523	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3194912	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2908627	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	42777	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5973	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	57777	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11295	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	327240	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	319552	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	655522	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	615846	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	4521574	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	2743317	usd
	us-gaap	Operating Expenses OperatingExpenses	7670105	usd
	us-gaap	Operating Expenses OperatingExpenses	5718480	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	1925505	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	1081117	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	3527529	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	2103801	usd
CY2023Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-2468350	usd
CY2022Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	688319	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-2657717	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	188176	usd
CY2023Q3	ELTP	Change In Fair Value Of Stockbased Liabilities ChangeInFairValueOfStockbasedLiabilities	-2066820	usd
	ELTP	Change In Fair Value Of Stockbased Liabilities ChangeInFairValueOfStockbasedLiabilities	-2066820	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	130438	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	242753	usd
	us-gaap	Interest Expense InterestExpense	249850	usd
	us-gaap	Interest Expense InterestExpense	459540	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	7320	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	43	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	10836	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	172	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4658288	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	445609	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4963551	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-271192	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2732783	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1526726	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1436022	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1832609	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-17667384	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11587	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-17512432	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11587	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	14934601	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	1515139	usd
	us-gaap	Net Income Loss NetIncomeLoss	16076410	usd
	us-gaap	Net Income Loss NetIncomeLoss	1821022	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1013915081	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1012228256	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1013915081	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1011762632	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1019316919	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1012228256	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1016944870	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1011762632	shares
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	28960260	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	1141809	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	30117069	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	14934601	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	42777	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	45094447	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	25222027	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	305883	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5322	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	25533232	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	1515139	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5974	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	60000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	77062	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	27191407	usd
	us-gaap	Net Income Loss NetIncomeLoss	16076410	usd
	us-gaap	Net Income Loss NetIncomeLoss	1821022	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	655522	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	615846	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	30798	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	11163	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	56272	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-2657717	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	188176	usd
	ELTP	Change In Fair Value Of Stockbased Liabilities ChangeInFairValueOfStockbasedLiabilities	-2066820	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	57777	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	11296	usd
	ELTP	Noncash Rent Expense And Lease Accretion NoncashRentExpenseAndLeaseAccretion	655	usd
	ELTP	Noncash Rent Expense And Lease Accretion NoncashRentExpenseAndLeaseAccretion	602	usd
	ELTP	Deferred Income Tax Asset DeferredIncomeTaxAsset	17261347	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7431310	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1171625	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5673668	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	727116	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-677224	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-307098	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	5205905	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	274453	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-6668	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-6670	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-12751	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-55104	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2945753	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	937898	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5199696	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5199696	usd
	us-gaap	Repayments Of First Mortgage Bond RepaymentsOfFirstMortgageBond	125000	usd
	us-gaap	Repayments Of First Mortgage Bond RepaymentsOfFirstMortgageBond	115000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	4000000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	14550000	usd
	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	97275	usd
	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	153400	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3777725	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14281600	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	831972	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	10019802	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8244681	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8940396	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9076653	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18960198	usd
	us-gaap	Interest Paid Net InterestPaidNet	119412	usd
	us-gaap	Interest Paid Net InterestPaidNet	459540	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	127522	usd
	us-gaap	Stock Issued1 StockIssued1	137067	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14157185	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8585763	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	23137261	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16258671	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6341228	usd
CY2023Q3	us-gaap	Restricted Cash RestrictedCash	422750	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	412434	usd
CY2023	us-gaap	Exploration Abandonment And Impairment Expense ExplorationAbandonmentAndImpairmentExpense	292807	usd
	us-gaap	Exploration Abandonment And Impairment Expense ExplorationAbandonmentAndImpairmentExpense	0	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6341228	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6341228	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6634035	usd
CY2023	ELTP	Finitelived Intangible Assets Impairment FinitelivedIntangibleAssetsImpairment	-292807	usd
	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	These tax benefits are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution
	ELTP	Average Customer Payment Percentage AverageCustomerPaymentPercentage	0.9996	pure
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	23100000	usd
	ELTP	Estimated Allowance EstimatedAllowance	125000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	1000000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	14934601	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1515139	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	16076410	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1821022	usd
CY2022Q3	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	688319	usd
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	188176	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	14934601	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	2203458	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	16076410	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	2009198	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1013915081	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1012228256	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1013915081	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1011762632	shares
CY2023Q3	us-gaap	Dilutive Securities DilutiveSecurities	5401838	usd
	us-gaap	Dilutive Securities DilutiveSecurities	3029789	usd
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1019316919	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1012228256	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1016944870	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1011762632	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	521711	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-2657717	usd
CY2023Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	3179428	usd
CY2022Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	936837	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	188176	usd
CY2022Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	748661	usd
	ELTP	Revenue Of Percent RevenueOfPercent	0.0054	pure
CY2023Q3	srt	Financing Receivable Before Allowance For Credit Loss To Total Percent FinancingReceivableBeforeAllowanceForCreditLossToTotalPercent	0.0054	pure
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	6654206	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2352330	usd
CY2023Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	1355355	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	1791311	usd
CY2023Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	7214823	usd
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	5407075	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	15224384	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	9550716	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	365000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	119404	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11158268	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5047726	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25011838	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25012493	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15241857	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14586335	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9769981	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10426158	usd
CY2023Q3	us-gaap	Depreciation Depreciation	327240	usd
CY2022Q3	us-gaap	Depreciation Depreciation	316007	usd
	us-gaap	Depreciation Depreciation	655522	usd
	us-gaap	Depreciation Depreciation	608755	usd
CY2023Q3	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	6405153	usd
CY2023Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	4125000	usd
CY2023Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	250000	usd
CY2023Q3	ELTP	Codevelopment Profit Split Accrued CodevelopmentProfitSplitAccrued	3388800	usd
CY2023Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	414989	usd
CY2023Q3	ELTP	Accrued Consultant Contract Fees AccruedConsultantContractFees	10000	usd
CY2023Q1	ELTP	Accrued Consultant Contract Fees AccruedConsultantContractFees	193333	usd
CY2023Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	100000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	125000	usd
CY2023Q3	ELTP	Accrued Director Dues AccruedDirectorDues	75000	usd
CY2023Q1	ELTP	Accrued Director Dues AccruedDirectorDues	70000	usd
CY2023Q3	us-gaap	Litigation Reserve Current LitigationReserveCurrent	70000	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	494315	usd
CY2023Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	93832	usd
CY2022Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	83686	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	171070	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	261265	usd
CY2023Q3	us-gaap	Deferred Revenue DeferredRevenue	25555	usd
CY2023Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13333	usd
CY2023Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	12222	usd
CY2023Q1	us-gaap	Deferred Revenue DeferredRevenue	32223	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13333	usd
CY2023Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	18890	usd
CY2020Q4	ELTP	Operating Lease Renewal Term OperatingLeaseRenewalTerm	The Pompano Office Lease has a term of three years, ending on October 31, 2023. The Pompano Office Lease was extended for one additional year on November 1, 2023 ending on October 31, 2024.
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1899	usd
CY2023Q3	ELTP	Operating Lease Assets OperatingLeaseAssets	1899	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2163	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2163	usd
CY2023Q3	us-gaap	Payments For Rent PaymentsForRent	0	usd
CY2022Q3	us-gaap	Payments For Rent PaymentsForRent	0	usd
	us-gaap	Payments For Rent PaymentsForRent	0	usd
	us-gaap	Payments For Rent PaymentsForRent	58248	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2163	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2163	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2163	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y1M6D
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.06	pure
	ELTP	Effective Income Tax Rate Change In Valuation Allowance EffectiveIncomeTaxRateChangeInValuationAllowance	0.21	pure
CY2023Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.1521
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.1521
CY2023Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P3Y7M6D
CY2023Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P4Y1M6D
CY2023Q1	ELTP	Stock Based Compensation StockBasedCompensation	4278333	usd
	ELTP	Increase Decrease In Stock Based Liabilities IncreaseDecreaseInStockBasedLiabilities	1973905	usd
CY2023Q3	ELTP	Stock Based Compensation StockBasedCompensation	6252238	usd
CY2023Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.80	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.80	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.79	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.80	pure
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0427	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0427	pure
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0432	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0432	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0299	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0401	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15370000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.07
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M24D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4000000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.09
	ELTP	Sharebased Compensation Arrangement By Sharebased Payment Award Weighted Average Remaining Contractual Term Granted SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAverageRemainingContractualTermGranted	P10Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	3840000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.07
	ELTP	Sharebased Compensation Arrangement By Sharebased Payment Award Weighted Average Remaining Contractual Term Expired And Forfeited SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAverageRemainingContractualTermExpiredAndForfeited	P1Y9M18D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15530000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.05
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y2M12D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	717706	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	343334	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.19
	ELTP	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableOutstandingWeightedAverageRemainingContractualTerm	P4Y10M24D
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	978	usd
CY2023Q3	ELTP	Price Difference Between Exercise Price And Quoted Price PriceDifferenceBetweenExercisePriceAndQuotedPrice	0.04
CY2023Q1	ELTP	Price Difference Between Exercise Price And Quoted Price PriceDifferenceBetweenExercisePriceAndQuotedPrice	0.03
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	164105	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y2M12D
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-17500000	usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0.0	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-17700000	usd
CY2023Q3	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0.0	usd
	ELTP	Discrete Tax Benefit DiscreteTaxBenefit	17300000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2044144	usd

Files In Submission

Name	View Source	Status
eltp-20230930_pre.xml	Edgar Link	unprocessable
eltp-20230930_cal.xml	Edgar Link	unprocessable
eltp-20230930_lab.xml	Edgar Link	unprocessable
eltp-20230930_def.xml	Edgar Link	unprocessable
0001493152-23-041124-index-headers.html	Edgar Link	pending
0001493152-23-041124-index.html	Edgar Link	pending
0001493152-23-041124.txt	Edgar Link	pending
0001493152-23-041124-xbrl.zip	Edgar Link	pending
eltp-20230930.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2023 Q4 Form 10-Q Financial Statement

#000149315223041124 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2023 Q4 Form 10-Q Financial Statement

#000149315223041124 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp